Annual report pursuant to Section 13 and 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.21.1
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
 12 Months Ended
Nov. 04, 2020
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Dec. 31, 2020
Dec. 31, 2019
Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]                
Payments for Royalties $ 20,000,000   $ 8,000,000          
Due to Related Parties, Current           $ 31,515,000 $ 27,400,000  
Program Rights Obligations, Current   $ 8,000,000            
Interest Payable               $ 1,000,000
Debt Instrument, Maturity Date     Nov. 04, 2020          
License termination date   May 02, 2020            
Debt Instrument, Periodic Payment, Principal           28,000,000    
Debt Instrument, Increase, Accrued Interest           3,500,000    
Non-cash licensed technology impairment charge           32,916,000  
Amortization of intangible assets           1,400,000 $ 5,200,000  
Abeona Therapeutics LLC [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Finite-lived intangible asset, useful life         20 years      
Original License Agreement [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Program Rights Obligations, Current               10,000,000
Eb Agreement [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Program Rights Obligations, Current               3,000,000
Eb Agreement [Member] | Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1                
Indefinite-lived Intangible Assets [Line Items]                
Program Rights Obligations, Current               $ 8,000,000
REGENXBIO [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Due remains value           28,000,000    
Licensing Agreements [Member] | REGENXBIO [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Royalty Expense       $ 180,000,000        
Payments for Royalties $ 20,000,000     60,000,000        
IncomeTax Reconciliation Current Year Reserve       10,000,000        
Due to Related Parties, Current       $ 10,000,000        
Finite-lived intangible asset, useful life       8 years        
Loss Contingency Accrual           8,000,000    
Payments for Legal Settlements           $ 20,000,000    
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]                
Indefinite-lived Intangible Assets [Line Items]                
Debt Instrument, Face Amount       $ 100,000,000